Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Mol Pharm ; 19(9): 3187-3198, 2022 09 05.
Artigo em Inglês | MEDLINE | ID: mdl-35939328

RESUMO

As the most common subtype in ovarian malignancies, high-grade serous ovarian cancer (HGSOC) made less therapeutic progress in past decades due to the lack of effective drug-able targets. Herein, an effective linoleic acid (LA) and glucosamine (GlcN) hybrid (LA-GlcN) was synthesized for the treatment of HGSOC. The GlcN was introduced to recognize the glucose transporter 1 (GLUT 1) overexpressed in tumor cells to enhance the uptake of LA-GlcN, and the unsaturated LA was employed to trigger ferroptosis by iron-dependent lipid peroxidation. Since the iron content of HGSOC was ∼5 and 2 times, respectively, higher than that of the normal ovarian cells and low-grade serous ovarian cancer cells, these excess irons make them a good target to enhance the ferroptosis of LA-GlcN. The in vitro study demonstrated that LA-GlcN could selectively kill HGSOC cells without affecting normal cells; the in vivo study revealed that LA-GlcN at the dose of 50 mg kg-1 achieved a comparable tumor inhibition as doxorubicin hydrochloride (4 mg kg-1) while the overall survival of mice was extended largely due to the low toxicity, and when the dose was increased to 100 mg kg-1, the therapeutic outcomes could be improved further. This dietary hybrid which targets the excess endogenous iron to activate ferroptosis represents a promising drug for HGSOC treatment.


Assuntos
Cistadenocarcinoma Seroso , Ferroptose , Neoplasias Ovarianas , Animais , Feminino , Glucosamina , Humanos , Ferro , Ácido Linoleico/uso terapêutico , Camundongos , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/patologia
2.
Bioorg Chem ; 129: 106167, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36166897

RESUMO

Prodrug development is of great interest in cancer therapy. From bio-friendly standpoints, traceless prodrug activation would be an ideal approach for cancer treatment owning to the avoidance of byproduct which might induce side effects in living system. Here, we report a fully traceless strategy for cancer imaging and therapy via a metal-free bioorthogonal ligation triggered by nitroreductase (NTR) overexpressed in solid tumors. The reduction of nitro substrates to amines by NTR and further condensation of amines with aldehydes can be seamlessly combined to yield imine-based resveratrol (RSV) with water as the only byproduct. In comparison with RSV, this precursor exhibited not only the same level of anticancer efficiency both in vitro and in vivo under hypoxia, but also a high sensitivity to hypoxia and much lower perturbation towards normal cells, which holds a great potential of theranostic prodrug for cancer therapy.


Assuntos
Neoplasias , Pró-Fármacos , Humanos , Pró-Fármacos/farmacologia , Nitrorredutases , Neoplasias/diagnóstico por imagem , Neoplasias/tratamento farmacológico , Hipóxia , Aminas
3.
J Mater Chem B ; 12(15): 3719-3740, 2024 Apr 17.
Artigo em Inglês | MEDLINE | ID: mdl-38529844

RESUMO

Elevated glucose levels, multiple pro-inflammatory cytokines and the generation of excessive reactive oxygen species (ROS) are pivotal characteristics within the microenvironments of chronic periodontitis with diabetes mellitus (CPDM). Control of inflammation and modulation of immune system are required in the initial phase of CPDM treatment, while late severe periodontitis requires a suitable scaffold to promote osteogenesis, rebuild periodontal tissue and reduce alveolar bone resorption. Herein, a whole-course-repair system is introduced by an injectable hydrogel using phenylboronic acid functionalized oxidized sodium alginate (OSA-PBA) and carboxymethyl chitosan (CMC). Epigallocatechin-3-gallate (EGCG) was loaded to simultaneously adjust the mechanical property of the OSA-PBA/CMC + EGCG hydrogel (OPCE). This hydrogel has distinctive adaptability, injectability, and ROS/glucose-triggered release of EGCG, making it an ideal drug delivery carrier. As expected, OPCE hydrogel shows favourable antioxidant and anti-inflammatory properties, along with a regulatory influence on the phenotypic transition of macrophages, providing a favourable immune microenvironment. Apart from that, it provides a favourable mechanical support for osteoblast/osteoclast differentiation regulation at the late proliferation stage of periodontal regeneration. The practical therapeutic effects of OPCE hydrogels were also confirmed when applied for treating periodontitis in diabetic rats. In summary, OPCE hydrogel may be a promising whole-course-repair system for the treatment of CPDM.


Assuntos
Catequina , Periodontite Crônica , Diabetes Mellitus Experimental , Sistemas de Liberação de Medicamentos , Glucose , Espécies Reativas de Oxigênio , Glucose/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Periodontite Crônica/complicações , Periodontite Crônica/tratamento farmacológico , Diabetes Mellitus Experimental/complicações , Animais , Ratos , Catequina/administração & dosagem , Catequina/análogos & derivados , Catequina/farmacologia , Catequina/uso terapêutico , Reologia , Hidrogéis , Antioxidantes/metabolismo , Macrófagos/efeitos dos fármacos , Inflamação/tratamento farmacológico , Osteoclastos/citologia , Osteoblastos/citologia , Diferenciação Celular , Regeneração Óssea/efeitos dos fármacos , Microtomografia por Raio-X , Perda do Osso Alveolar/tratamento farmacológico , Sistemas de Liberação de Medicamentos/métodos , Alginatos , Bases de Schiff , Masculino , Ratos Sprague-Dawley , Células RAW 264.7 , Camundongos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA